Table 2. Baseline characteristics for the groups of patients with positive and negative urine culture.
| Characteristic Total N = 608 |
N total | Positive urine culture N = 141 |
Negative urine culture N = 467 |
P value |
|---|---|---|---|---|
| N(%) | ||||
| Female gender | 176 (28.9) | 73 (51.8) | 103 (22.1) | <0.0001 |
| In care before/in 2007 | 378 (62.2) | 116 (82.3) | 262 (56.1) | <0.0001 |
| Risk group | ||||
| Heterosexual contacts | 122 (20.1) | 41 (29.1) | 81 (17.3) | <0.0001 |
| Homosexual contacts | 258 (42.2) | 28 (19.9) | 230 (49.2) | |
| Injecting drug use | 162 (26.6) | 52 (36.9) | 110 (23.5) | |
| Other | 18 (2.96) | 9 (6.4) | 9 (1.9) | |
| Unknown | 48 (7.9) | 11 (7.8) | 37 (7.9) | |
| Positive HCV antibody | 169 (29.4) | 65 (48.1) | 104 (23.7) | <0.0001 |
| Positive HCV RNA | 118 (19.4) | 38 (26.9) | 80 (17.1) | 0.01 |
| Baseline lymphocyte CD4+ count <350 cells/μl | 270 (44.4) | 71 (50.4) | 199 (42.6) | 0.10 |
| Antiretroviral therapy—yes/no |
588(96.7)/ 20(3.3) |
136(96,45)/ 5(3.5) |
452(96.8)/ 15(3.2) |
0.79 |
| Fusion inhibitors | 7(1.2) | 1(0.7) | 6(1.3) | 0.68 |
| Integrase inhibitors | 9(1.5) | 1(0.7) | 8(1.8) | |
| Non-Nucleoside reverse transcriptase inhibitors | 147(25.2) | 32(23.5) | 115(25.7) | |
| Protease inhibitors | 420(72.0) | 102(75.0) | 318(71.1) | |
| Median (IQR) | ||||
| Age at registration in years | 31.6 (26.6–39.2) | 30.7 (24.9–39.3) | 31.9 (27.0–38.0) | 0.27 |
| Nadir lymphocyte CD4+ count in cells/ μl | 197 (86–306) | 139 (60–225) | 221 (107–322) | <0.0001 |
| Baseline lymphocyte CD4+ count in cells/ μl | 385 (204–565) | 344 (160–562) | 393 (228–570) | 0.13 |
| Baseline HIV RNA log copiel/ml |
4,26 (3,36–4,93) | 4,02(3,06–4,76) | 4,35(3,49–4,00) | 0.01 |
| Highest proteinuria n = 190 | 0.51 (0.28–1.26) | 0.93 (0.43–2.40) | 0.45 (0.25–0.96) | 0.002 |
| HCV RNA n = 118 log copies/ml |
5,99(5,20–6,49) | 6,01(5,06–6,39) | 5,99(5,28–6,50) | 0.47 |